S&P 500   4,276.73 (-0.66%)
DOW   33,989.13 (-0.48%)
QQQ   329.45 (-0.85%)
AAPL   175.02 (+1.15%)
MSFT   291.85 (-0.29%)
META   176.09 (-1.88%)
GOOGL   120.28 (-1.17%)
AMZN   142.56 (-1.53%)
TSLA   918.58 (-0.12%)
NVDA   184.14 (-2.46%)
NIO   20.30 (-2.92%)
BABA   90.48 (-2.34%)
AMD   98.48 (-1.72%)
MU   61.78 (-3.26%)
T   18.50 (-0.38%)
CGC   4.05 (+7.14%)
F   16.10 (-2.01%)
GE   79.99 (-1.33%)
DIS   123.45 (-1.21%)
AMC   22.75 (-8.30%)
PYPL   100.11 (-1.93%)
PFE   49.44 (-0.84%)
NFLX   241.92 (-1.53%)
S&P 500   4,276.73 (-0.66%)
DOW   33,989.13 (-0.48%)
QQQ   329.45 (-0.85%)
AAPL   175.02 (+1.15%)
MSFT   291.85 (-0.29%)
META   176.09 (-1.88%)
GOOGL   120.28 (-1.17%)
AMZN   142.56 (-1.53%)
TSLA   918.58 (-0.12%)
NVDA   184.14 (-2.46%)
NIO   20.30 (-2.92%)
BABA   90.48 (-2.34%)
AMD   98.48 (-1.72%)
MU   61.78 (-3.26%)
T   18.50 (-0.38%)
CGC   4.05 (+7.14%)
F   16.10 (-2.01%)
GE   79.99 (-1.33%)
DIS   123.45 (-1.21%)
AMC   22.75 (-8.30%)
PYPL   100.11 (-1.93%)
PFE   49.44 (-0.84%)
NFLX   241.92 (-1.53%)
S&P 500   4,276.73 (-0.66%)
DOW   33,989.13 (-0.48%)
QQQ   329.45 (-0.85%)
AAPL   175.02 (+1.15%)
MSFT   291.85 (-0.29%)
META   176.09 (-1.88%)
GOOGL   120.28 (-1.17%)
AMZN   142.56 (-1.53%)
TSLA   918.58 (-0.12%)
NVDA   184.14 (-2.46%)
NIO   20.30 (-2.92%)
BABA   90.48 (-2.34%)
AMD   98.48 (-1.72%)
MU   61.78 (-3.26%)
T   18.50 (-0.38%)
CGC   4.05 (+7.14%)
F   16.10 (-2.01%)
GE   79.99 (-1.33%)
DIS   123.45 (-1.21%)
AMC   22.75 (-8.30%)
PYPL   100.11 (-1.93%)
PFE   49.44 (-0.84%)
NFLX   241.92 (-1.53%)
S&P 500   4,276.73 (-0.66%)
DOW   33,989.13 (-0.48%)
QQQ   329.45 (-0.85%)
AAPL   175.02 (+1.15%)
MSFT   291.85 (-0.29%)
META   176.09 (-1.88%)
GOOGL   120.28 (-1.17%)
AMZN   142.56 (-1.53%)
TSLA   918.58 (-0.12%)
NVDA   184.14 (-2.46%)
NIO   20.30 (-2.92%)
BABA   90.48 (-2.34%)
AMD   98.48 (-1.72%)
MU   61.78 (-3.26%)
T   18.50 (-0.38%)
CGC   4.05 (+7.14%)
F   16.10 (-2.01%)
GE   79.99 (-1.33%)
DIS   123.45 (-1.21%)
AMC   22.75 (-8.30%)
PYPL   100.11 (-1.93%)
PFE   49.44 (-0.84%)
NFLX   241.92 (-1.53%)
OTCMKTS:CUBT

Curative Biotechnology - CUBT Stock Forecast, Price & News

$0.03
0.00 (0.00%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.03
$0.03
50-Day Range
$0.03
$0.04
52-Week Range
$0.02
$0.14
Volume
177,380 shs
Average Volume
266,524 shs
Market Capitalization
$18.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Curative Biotechnology

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

Receive CUBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curative Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

CUBT Stock News Headlines

See More Headlines
Receive CUBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curative Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

CUBT Company Calendar

Today
8/17/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CUBT
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$18.81 million
Optionable
Not Optionable
Beta
-22.78

Key Executives

  • Paul M. Michael
    Executive Chairman & President
  • I. Richard Garr
    Chief Executive Officer & General Counsel
  • Ron Bordens
    Executive VP-Technical Operations & Manufacturing
  • Barry A. Ginsberg
    Vice Chairman & Chief Strategy Officer













CUBT Stock - Frequently Asked Questions

How have CUBT shares performed in 2022?

Curative Biotechnology's stock was trading at $0.0520 at the beginning of 2022. Since then, CUBT shares have decreased by 36.7% and is now trading at $0.0329.
View the best growth stocks for 2022 here
.

Are investors shorting Curative Biotechnology?

Curative Biotechnology saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 23,400 shares, an increase of 42.7% from the July 15th total of 16,400 shares. Based on an average daily volume of 674,900 shares, the days-to-cover ratio is presently 0.0 days.
View Curative Biotechnology's Short Interest
.

What is Curative Biotechnology's stock symbol?

Curative Biotechnology trades on the OTCMKTS under the ticker symbol "CUBT."

How do I buy shares of Curative Biotechnology?

Shares of CUBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Curative Biotechnology's stock price today?

One share of CUBT stock can currently be purchased for approximately $0.03.

How much money does Curative Biotechnology make?

Curative Biotechnology (OTCMKTS:CUBT) has a market capitalization of $18.81 million.

How can I contact Curative Biotechnology?

Curative Biotechnology's mailing address is 49 SW Flagler Avenue Suite 302, Stuart FL, 34994. The official website for the company is curativebiotech.com. The company can be reached via phone at (561) 418-7725, via email at investorrelations@connectyx.com, or via fax at 866-900-1002.

This page (OTCMKTS:CUBT) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.